Roman K. Thomas

36.3k total citations · 1 hit paper
95 papers, 5.7k citations indexed

About

Roman K. Thomas is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Roman K. Thomas has authored 95 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 44 papers in Oncology and 37 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Roman K. Thomas's work include Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Research Studies (23 papers) and Cancer Genomics and Diagnostics (21 papers). Roman K. Thomas is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Research Studies (23 papers) and Cancer Genomics and Diagnostics (21 papers). Roman K. Thomas collaborates with scholars based in Germany, United States and United Kingdom. Roman K. Thomas's co-authors include Volker Diehl, Jürgen Wolf, Daniel Ré, Johannes M. Heuckmann, Martin Peifer, Julie George, William Pao, Élisabeth Brambilla, Martin L. Sos and Pablo Ernesto Pérez and has published in prestigious journals such as The Lancet, Nucleic Acids Research and Journal of Clinical Investigation.

In The Last Decade

Roman K. Thomas

93 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

2019 718 citations Julie George, Pierre P. Massion et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roman K. Thomas Germany	37	3.1k	2.6k	2.0k	1.1k	751	95	5.7k
Christine M. Lovly United States	44	3.7k 1.2×	3.3k 1.3×	3.1k 1.5×	1.4k 1.3×	583 0.8×	143	6.8k
David S. Rickman United States	34	1.4k 0.5×	2.8k 1.1×	1.6k 0.8×	1.6k 1.4×	855 1.1×	63	5.6k
Michael J. Pishvaian United States	40	3.8k 1.2×	1.9k 0.7×	1.1k 0.5×	1.5k 1.4×	614 0.8×	216	5.8k
Paul K. Paik United States	31	3.0k 1.0×	2.2k 0.8×	3.5k 1.7×	1.1k 1.0×	561 0.7×	155	5.6k
Teresa Macarulla Spain	42	6.4k 2.1×	2.9k 1.1×	2.2k 1.1×	2.3k 2.1×	1.0k 1.4×	315	8.7k
Laura D. Wood United States	46	5.2k 1.7×	3.1k 1.2×	1.6k 0.8×	2.9k 2.6×	661 0.9×	155	8.6k
E. Gabriela Chiorean United States	42	4.7k 1.5×	2.1k 0.8×	1.5k 0.7×	1.7k 1.5×	441 0.6×	209	7.1k
Bijoyesh Mookerjee United States	30	3.7k 1.2×	4.1k 1.5×	2.2k 1.1×	2.3k 2.1×	781 1.0×	85	7.4k
Yun Wu United States	36	2.5k 0.8×	2.1k 0.8×	870 0.4×	1.8k 1.6×	694 0.9×	105	5.2k
Melissa L. Johnson United States	42	5.0k 1.6×	2.3k 0.9×	3.4k 1.7×	1.1k 1.0×	450 0.6×	359	7.1k

Countries citing papers authored by Roman K. Thomas

Since Specialization

Citations

This map shows the geographic impact of Roman K. Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roman K. Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roman K. Thomas more than expected).

Fields of papers citing papers by Roman K. Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roman K. Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roman K. Thomas. The network helps show where Roman K. Thomas may publish in the future.

Co-authorship network of co-authors of Roman K. Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Roman K. Thomas. A scholar is included among the top collaborators of Roman K. Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roman K. Thomas. Roman K. Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kaiser, Laura, Giulia Barbiera, Roman K. Thomas, et al.. (2025). DynaTag for efficient mapping of transcription factors in low-input samples and at single-cell resolution. Nature Communications. 16(1). 6585–6585. 1 indexed citations

Fischer, Rieke, Julie George, Hans Anton Schloesser, et al.. (2024). BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer—Results from the SCLC TMB^high cohort.. Journal of Clinical Oncology. 42(16_suppl). 8099–8099. 1 indexed citations

Lorenz, Carina, Maria Cartolano, Dennis Plenker, et al.. (2023). Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer. Cancer Research. 83(15). 2471–2479. 7 indexed citations

Nogová, Lucia, Florian Malchers, Axel M. Hillmer, et al.. (2023). 1329P FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC. Annals of Oncology. 34. S767–S767. 2 indexed citations

Valencia, Karmele, Álvaro Teijeira, Cristina Bértolo, et al.. (2022). DSTYK inhibition increases the sensitivity of lung cancer cells to T cell–mediated cytotoxicity. The Journal of Experimental Medicine. 219(12). 7 indexed citations

George, Julie, Andreas H. Scheel, Hans Anton Schloesser, et al.. (2022). 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort. Annals of Oncology. 33. S1025–S1025. 1 indexed citations

Metzger, Eric, Matthias Fahrner, Julie George, et al.. (2020). Depletion of histone methyltransferase KMT9 inhibits lung cancer cell proliferation by inducing non-apoptotic cell death. Cancer Cell International. 20(1). 52–52. 25 indexed citations

Malchers, Florian, Meryem S. Ercanoglu, Roberta Castiglione, et al.. (2017). Mechanisms of Primary Drug Resistance in FGFR1 -Amplified Lung Cancer. Clinical Cancer Research. 23(18). 5527–5536. 41 indexed citations

George, Julie, Motonobu Saito, Koji Tsuta, et al.. (2016). Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer. Clinical Cancer Research. 23(5). 1220–1226. 93 indexed citations

10.

Heuckmann, Johannes M. & Roman K. Thomas. (2015). A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. Annals of Oncology. 26(9). 1830–1837. 37 indexed citations

11.

Chatterjee, Sampurna, Lukas C. Heukamp, Jakob Schöttle, et al.. (2013). Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. Journal of Clinical Investigation. 123(4). 1732–1740. 164 indexed citations

12.

Heuckmann, Johannes M., Hyatt Balke‐Want, Florian Malchers, et al.. (2012). Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants. Clinical Cancer Research. 18(17). 4682–4690. 201 indexed citations

13.

Lovly, Christine M., Johannes M. Heuckmann, Elisa de Stanchina, et al.. (2011). Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors. Cancer Research. 71(14). 4920–4931. 177 indexed citations

14.

Zander, Thomas, Andrea Hofmann, Andrea Staratschek‐Jox, et al.. (2011). Blood-Based Gene Expression Signatures in Non–Small Cell Lung Cancer. Clinical Cancer Research. 17(10). 3360–3367. 51 indexed citations

15.

Heuckmann, Johannes M., Michael Hölzel, Martin L. Sos, et al.. (2011). ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors. Clinical Cancer Research. 17(23). 7394–7401. 147 indexed citations

16.

Sos, Martin L., Haridas B. Rode, Stefanie Heynck, et al.. (2010). Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation. Cancer Research. 70(3). 868–874. 175 indexed citations

17.

Ocak, Sebahat, Martin L. Sos, Roman K. Thomas, & Pierre P. Massion. (2009). High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. European Respiratory Journal. 34(2). 489–506. 33 indexed citations

18.

Nogová, Lucia, Ronald Boellaard, Carsten Kobe, et al.. (2009). Downregulation of ¹⁸F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non–Small Cell Lung Cancer with the mTOR Inhibitor Everolimus. Journal of Nuclear Medicine. 50(11). 1815–1819. 24 indexed citations

19.

Lin, William M., Alissa C. Baker, Rameen Beroukhim, et al.. (2008). Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma. Cancer Research. 68(3). 664–673. 215 indexed citations

20.

Ji, Hongbin, Zhenxiong Wang, Samanthi A. Perera, et al.. (2007). Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models. Cancer Research. 67(10). 4933–4939. 137 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact